FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug

AstraZeneca Plc failed to persuade a US regulatory review panel about the benefits of its novel breast cancer medicine, throwing a hurdle in front of a key drug in the company’s pipeline.